Boenning & Scattergood Inc. Has $3.85 Million Holdings in Becton Dickinson and Co (NYSE:BDX)

Boenning & Scattergood Inc. lessened its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 2.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,228 shares of the medical instruments supplier’s stock after selling 452 shares during the period. Becton Dickinson and comprises 1.1% of Boenning & Scattergood Inc.’s holdings, making the stock its 18th largest holding. Boenning & Scattergood Inc.’s holdings in Becton Dickinson and were worth $3,852,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Whittier Trust Co. boosted its position in Becton Dickinson and by 0.6% in the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock valued at $1,760,000 after buying an additional 40 shares in the last quarter. ProVise Management Group LLC boosted its position in Becton Dickinson and by 2.2% in the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock valued at $479,000 after buying an additional 41 shares in the last quarter. Pitcairn Co. boosted its position in Becton Dickinson and by 1.3% in the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock valued at $813,000 after buying an additional 41 shares in the last quarter. Ropes Wealth Advisors LLC raised its stake in shares of Becton Dickinson and by 0.6% during the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock valued at $1,714,000 after acquiring an additional 43 shares during the last quarter. Finally, Armor Investment Advisors LLC raised its stake in shares of Becton Dickinson and by 0.5% during the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock valued at $2,335,000 after acquiring an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 84.23% of the company’s stock.

In other Becton Dickinson and news, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total value of $347,618.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the sale, the senior vice president now directly owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The disclosure for this sale can be found here. Insiders have sold 37,249 shares of company stock valued at $9,616,803 in the last three months. 0.12% of the stock is owned by insiders.

Shares of NYSE BDX opened at $252.68 on Tuesday. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $264.74. The firm has a fifty day simple moving average of $253.77 and a 200 day simple moving average of $246.00. The company has a market capitalization of $68.26 billion, a PE ratio of 22.95, a P/E/G ratio of 1.62 and a beta of 1.12. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter last year, the firm earned $2.91 earnings per share. Becton Dickinson and’s quarterly revenue was up 1.7% on a year-over-year basis. As a group, equities analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date was Friday, September 6th. Becton Dickinson and’s dividend payout ratio is presently 27.97%.

Several research firms have recently issued reports on BDX. Raymond James raised their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Wells Fargo & Co raised their price target on shares of Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Finally, Piper Jaffray Companies dropped their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $266.55.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.